Engineering naphthalimide-cyanine integrated near-infrared dye into ROS-responsive nanohybrids for tumor PDT/PTT/chemotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35310343.
- Also identified by DOI 10.1016/j.bioactmat.2021.12.009 and PMC identifier 8892148.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Photodynamic (PDT) and photothermal therapies (PTT) are emerging treatments for tumour ablation. Organic dyes such as porphyrin, chlorin, phthalocyanine, boron-dipyrromethene and cyanine are the clinically or preclinically used photosensitizer or photothermal agents. Development of structurally diverse near-infrared dyes with long absorption wavelength is of great significance for PDT and PTT. Herein, we report a novel near-infrared dye <b>ML880</b> with naphthalimide modified cyanine skeleton. The introduction of naphthalimide moiety results in stronger electron delocalization and larger redshift in emission compared with <b>IR820</b>. Furthermore, <b>ML880</b> is co-loaded with chemotherapeutic drug into ROS-responsive mesoporous organosilica (<b>RMON</b>) to construct nanomedicine <b>NBD&ML@RMON</b>, which exhibits remarkable tumor inhibition effects through PDT/PTT/chemotherapy in vivo.